<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3164">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03065712</url>
  </required_header>
  <id_info>
    <org_study_id>PROTOCOL VERSION 2</org_study_id>
    <nct_id>NCT03065712</nct_id>
  </id_info>
  <brief_title>Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET</brief_title>
  <official_title>Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET and Predictive Measure for Endocrine Therapy Response in Patients With Newly Diagnosed Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rathan Subramaniam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will formally address the hypothesis that FES-PET/CT measurement of ER expression
      predicts clinical benefit of first-line endocrine therapy in newly diagnosed ER+ metastatic
      breast cancer patients and establishes the repeatability of FES PET/CT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Anticipated">February 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repeatablility coefficient</measure>
    <time_frame>Repeatable FES PET/CT scans are performed within 10 days</time_frame>
    <description>Maximum standardized uptake value repeatability coefficient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative Predictive Value</measure>
    <time_frame>6 months after treatment completion</time_frame>
    <description>Negative Predictive Value of baseline FES PET/CT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>FES PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm study that involves FES PET/CT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-Fluoroestradiol</intervention_name>
    <description>18F-Fluoroestradiol will be administered for PET/CT scan.</description>
    <arm_group_label>FES PET/CT</arm_group_label>
    <other_name>FES</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a. Patients must be over 18 years old and capable and willing to provide informed
             consent.

             b. Patients of childbearing potential must have a negative urine or serum pregnancy
             test within 7 days prior to PET/CT imaging per institution's standard of care; c. A
             female of child-bearing potential is any woman (regardless of sexual orientation,
             having undergone a tubal ligation, or remaining celibate by choice) who meets the
             following criteria; i. Has not undergone a hysterectomy or bilateral oophorectomy; or
             ii. Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,
             has had menses at any time in the preceding 12 consecutive months).

             d. Medically stable as judged by patient's physician. e. Life expectancy must be
             estimated at &gt; 6 months. f. Patients must have an ECOG performance status of 0-3
             (restricted to ECOG PS 0-2 if age &gt;70 years).

             g. Patients with known allergic or hypersensitivity reactions to previously
             administered radiopharmaceuticals of similar chemical or biologic composition to FES
             are NOT eligible.

             h. Patients with liver failure are NOT eligible. i. Patient must NOT be
             breast-feeding. j. Histologically confirmed metastatic breast cancer k. Primary tumor
             and/or metastatic site must be ER+ and may be progesterone-receptor positive (PgR+)
             or progesterone-receptor negative (PgR-) by IHC. Patients with a history of an
             estrogen-receptor negative (ER-) primary tumor and a documented ER+ metastatic site
             are eligible.

             l. Patients receiving molecular targeted therapy (such as everolimus or palbociclib)
             or HER2 directed therapy, in addition to endocrine therapy are NOT eligible.

             m. Patients with a history of adjuvant endocrine therapy is allowed, as long as the
             date of diagnosis of metastatic disease is &gt; 2 years following initiation of adjuvant
             endocrine therapy. Patients who develop metastatic disease while still receiving
             adjuvant endocrine therapy must have a change in the type of endocrine agent used for
             subsequent metastatic disease treatment. Patients on blocking adjuvant therapy (with
             a blocking agent such as toremifene or tamoxifen) must be off the agents for a
             minimum of 60 days to allow for adequate uptake of FES n. Patients with human
             epidermal growth factor-2 positive (HER2+) metastatic tumors are NOT eligible o.
             Postmenopausal women, men, or premenopausal women for whom endocrine therapy alone
             (tamoxifen, aromatase inhibitor (AI) with or without ovarian suppression is planned
             for standard clinical care, after FES-PET/CT is completed p. Disease may be
             measurable (by RECIST 1.1 criteria) or non-measurable but must be present in at least
             one non-liver site, 1.5 cm or greater and visualized on PET/CT with
             [18F]-fluorodeoxyglucose (FDG). Patients with effusion only disease or disease only
             in the liver are not eligible for the study q. Patient must be able to lie still for
             a 20 to 30 minute PET/CT scan.

        Exclusion Criteria:

          -  Patients not meeting inclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rathan Subramaniam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayobami Odu, MBBS</last_name>
    <phone>214-645-1568</phone>
    <email>Ayobami.Odu@UTSouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Radiology Clinical Trials Office</last_name>
    <phone>214-645-1568</phone>
    <email>RadiologyCTO@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clements University Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayobami Odu, MBBS</last_name>
      <phone>214-645-1568</phone>
      <email>Ayobami.Odu@UTSouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>radiology Clinical Trials Office</last_name>
      <phone>214-645-1568</phone>
      <email>RadiologyCTO@utsouthwestern.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988 Oct;169(1):45-8.</citation>
    <PMID>3262228</PMID>
  </reference>
  <reference>
    <citation>Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001 Jun 1;19(11):2797-803.</citation>
    <PMID>11387350</PMID>
  </reference>
  <reference>
    <citation>Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996 Jun;2(6):933-9.</citation>
    <PMID>9816253</PMID>
  </reference>
  <reference>
    <citation>Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2793-9. Epub 2006 May 8.</citation>
    <PMID>16682724</PMID>
  </reference>
  <reference>
    <citation>Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med. 2011 Oct;52(10):1541-9. doi: 10.2967/jnumed.111.091439. Epub 2011 Sep 8.</citation>
    <PMID>21903739</PMID>
  </reference>
  <reference>
    <citation>Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M, Katzenellenbogen JA, Welch MJ, Siegel BA. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2009 Feb;113(3):509-17. doi: 10.1007/s10549-008-9953-0. Epub 2008 Mar 9.</citation>
    <PMID>18327670</PMID>
  </reference>
  <reference>
    <citation>Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011 Jul 15;17(14):4799-805. doi: 10.1158/1078-0432.CCR-10-3321. Epub 2011 Jul 12.</citation>
    <PMID>21750198</PMID>
  </reference>
  <reference>
    <citation>Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol. 2014 Jun;16(3):431-40. doi: 10.1007/s11307-013-0699-7. Epub 2013 Oct 30.</citation>
    <PMID>24170452</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>February 20, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Rathan Subramaniam</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>PET/CT</keyword>
  <keyword>FES</keyword>
  <keyword>18F Fluoroestradiol</keyword>
  <keyword>Breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
